ClinicalTrials.gg
CompletedNCT00500266Updated Sep 16, 2011Results posted

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Pneumococcal Infections, sponsored by Pfizer. Completed at 59 sites in 3 countries. Open to participants aged 68 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-16.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,053
Allocation
Not applicable
Ages
68 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
7th of 44
1,053 · median 328
Started
2008
with 1 other
Phase 3
19 of 44
none open now
Registered
6th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 19 in phase 3, and was the 6th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 68 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • pneumococcal conjugate vaccine
  • vaccine
04

Who can participate

Ages eligible
68 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

MAIN INCLUSION CRITERIA:

  • Male or female aged 68 years or older
  • Determined by medical history, physical examination, and clinical judgment to be eligible for the study
  • Documented vaccination with 1 or more doses of pneumococcal vaccine at least 3 years before study enrollment

MAIN EXCLUSION CRITERIA:

  • Known history of severe reaction to a vaccine
  • Documented S pneumoniae infection within the past 5 years.
  • Known or suspected immunodeficiency or receiving treatment with therapy including cytotoxic agents or systemic
  • Serious chronic disorder including , severe requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator's opinion precludes the subject from participating in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,053 participants (actual)

Study arms

  • Experimental
    1

    13-valent Pneumococcal Conjugate Vaccine

    Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pre-specified Local Reactions

    Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters\[cm\]); moderate(5.1-10.0 cm); severe(\>10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.

    Time frame: Days 1 through 14

  2. Percentage of Participants With Pre-specified Systemic Events

    Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(\>=38 degrees Celsius\[C\]), chills, rash, vomiting(mild:1-2 times daily; moderate:\>2 times daily; severe:prevents daily activity) decreased appetite \& diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:\>=6 loose stools/day) reported. Participants may be represented in \>1 category.

    Time frame: Days 1 through 14

  3. Percentage of Participants Taking Pain or Antipyretic Medication

    Use of pain or antipyretic medication was collected by the participants using an electronic diary.

    Time frame: Days 1 through 14

07

Results

Posted Sep 16, 2011

Participant flow

Participant flow — Overall Study
Milestone13vPnC
Started1053
Treated1049
Completed1040
Not completed13
Withdrew: Death3
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject3
Withdrew: Assigned, not treated4

Outcome measures

PrimaryPercentage of Participants With Pre-specified Local Reactions

Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters\[cm\]); moderate(5.1-10.0 cm); severe(\>10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.

Time frame:
Days 1 through 14
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pre-specified Local Reactions
Percentage of Participants13vPnC
Redness: Any (n=666)14.3 (11.7 to 17.2)
Redness: Mild (n=660)12.6 (10.1 to 15.3)
Redness: Moderate (n=649)6.5 (4.7 to 8.6)
Redness: Severe (n=638)1.1 (0.4 to 2.2)
Swelling: Any (n=664)12.8 (10.4 to 15.6)
Swelling: Mild (n=658)10.9 (8.7 to 13.6)
Swelling: Moderate (n=651)5.5 (3.9 to 7.6)
Swelling: Severe (n=636)0.6 (0.2 to 1.6)
Pain: Any (n=777)51.0 (47.4 to 54.5)
Pain: Mild (n=770)49.4 (45.8 to 52.9)
Pain: Moderate (n=656)9.0 (6.9 to 11.4)
Pain: Severe (n=634)0.2 (0.0 to 0.9)
Limitation of arm movement: Any (n=679)16.2 (13.5 to 19.2)
Limitation of arm movement: Mild (n=674)14.8 (12.2 to 17.7)
Limitation of arm movement: Moderate (n=636)1.6 (0.8 to 2.9)
Limitation of arm movement: Severe (n=640)1.6 (0.8 to 2.9)
Any local reaction (n=802)56.6 (53.1 to 60.1)
Any severe local reaction (n=643)2.6 (1.5 to 4.2)
PrimaryPercentage of Participants With Pre-specified Systemic Events

Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(\>=38 degrees Celsius\[C\]), chills, rash, vomiting(mild:1-2 times daily; moderate:\>2 times daily; severe:prevents daily activity) decreased appetite \& diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:\>=6 loose stools/day) reported. Participants may be represented in \>1 category.

Time frame:
Days 1 through 14
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pre-specified Systemic Events
Percentage of Participants13vPnC
Fever (any): >=38 degrees C (n=641)2.0 (1.1 to 3.4)
Fever: >=38 degrees C but <38.5 degrees C (n=636)0.8 (0.3 to 1.8)
Fever: >=38.5 degrees C but <39 degrees C (n=634)0.0 (0.0 to 0.6)
Fever: >=39 degrees C but <=40 degrees C (n=635)0.3 (0.0 to 1.1)
Fever: >40 degrees C (n=638)0.9 (0.3 to 2.0)
Fatigue: Any (n=733)34.4 (30.9 to 37.9)
Fatigue: Mild (n=710)28.7 (25.4 to 32.2)
Fatigue: Moderate (n=683)15.2 (12.6 to 18.1)
Fatigue: Severe (n=639)2.0 (1.1 to 3.5)
Headache: Any (n=702)26.1 (22.9 to 29.5)
Headache: Mild (n=696)24.1 (21.0 to 27.5)
Headache: Moderate (n=655)9.0 (6.9 to 11.5)
Headache: Severe (n=637)0.8 (0.3 to 1.8)
Chills (n=651)7.5 (5.6 to 9.8)
Rash (n=658)8.4 (6.4 to 10.7)
Vomiting: Any (vomiting present; n=638)0.9 (0.3 to 2.0)
Vomiting: Mild (1 to 2 times in 24 hours;n=637)0.8 (0.3 to 1.8)
Vomiting: Moderate (>2 times in 24 hours;n=635)0.2 (0.0 to 0.9)
Vomiting: Severe (prevents routine activity;n=634)0.0 (0.0 to 0.6)
Decreased appetite (n=668)11.2 (8.9 to 13.9)
Diarrhea: Any (diarrhea present; n=684)14.5 (11.9 to 17.3)
Diarrhea: Mild (2 to 3 loose stools/day; n=678)12.8 (10.4 to 15.6)
Diarrhea: Moderate (4 to 5 loose stools/day;n=644)3.4 (2.2 to 5.1)
Diarrhea: Severe (>=6 loose stools/day; n=635)0.3 (0.0 to 1.1)
New generalized muscle pain: Any (n=700)25.3 (22.1 to 28.7)
New generalized muscle pain: Mild (n=679)20.5 (17.5 to 23.7)
New generalized muscle pain: Moderate (n=658)7.9 (6.0 to 10.2)
New generalized muscle pain: Severe (n=636)0.6 (0.2 to 1.6)
Aggravated generalized muscle pain: Any (n=669)12.3 (9.9 to 15.0)
Aggravated generalized muscle pain: Mild (n=650)7.5 (5.6 to 9.8)
Aggravated generalized muscle pain:Moderate(n=655)6.4 (4.7 to 8.6)
Aggravated generalized muscle pain: Severe (n=639)1.4 (0.6 to 2.7)
New generalized joint pain: Any (n=665)12.8 (10.3 to 15.6)
New generalized joint pain: Mild (n=651)8.1 (6.2 to 10.5)
New generalized joint pain: Moderate (n=648)5.7 (4.1 to 7.8)
New generalized joint pain: Severe (n=637)0.8 (0.3 to 1.8)
Aggravated generalized joint pain: Any (n=661)9.7 (7.5 to 12.2)
Aggravated generalized joint pain: Mild (n=647)5.7 (4.1 to 7.8)
Aggravated generalized joint pain: Moderate(n=647)5.1 (3.5 to 7.1)
Aggravated generalized joint pain: Severe (n=637)1.1 (0.4 to 2.3)
Any systemic event (n=832)58.4 (55.0 to 61.8)
PrimaryPercentage of Participants Taking Pain or Antipyretic Medication

Use of pain or antipyretic medication was collected by the participants using an electronic diary.

Time frame:
Days 1 through 14
Reported as:
Number · Percentage of Participants
Percentage of Participants Taking Pain or Antipyretic Medication
Percentage of Participants13vPnC
Use of medication to treat pain (n=677)17.0 (14.2 to 20.0)
Use of medication to treat fever (n=655)6.4 (4.7 to 8.6)

Adverse events

Collected over Local reactions, systemic events recorded within 14 days post vaccination. AEs recorded from Visit(V) 1 to 2(29-43 days after V1). At V3(166-194 days after V1), only newly diagnosed chronic medical conditions recorded as AEs. SAEs recorded from V1 to V3.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC: Visit 1 to Visit 2—10/1,049 (1%)486/1,049 (46.3%)
13vPnC: 6-month Follow-up—41/1,049 (3.9%)77/1,049 (7.3%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
Event13vPnC: Visit 1 to Visit 213vPnC: 6-month Follow-up
Myocardial infarctionCardiac disorders0/10493/1049
PneumoniaInfections and infestations0/10493/1049
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/10493/1049
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/10490/1049
Atrial fibrillationCardiac disorders0/10492/1049
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10492/1049
Respiratory failureRespiratory, thoracic and mediastinal disorders0/10492/1049
BradyarrhythmiaCardiac disorders1/10491/1049
TachyarrhythmiaCardiac disorders1/10490/1049
GastritisGastrointestinal disorders1/10490/1049
Most frequent other events
Showing 10 of 209
Most frequent other events
Event13vPnC: Visit 1 to Visit 213vPnC: 6-month Follow-up
Pain (any)Skin and subcutaneous tissue disorders396/777—
Pain (mild)Skin and subcutaneous tissue disorders380/770—
Fatigue (any)General disorders252/733—
Fatigue (mild)General disorders204/710—
Headache (any)General disorders183/702—
New generalized muscle pain (any)General disorders177/700—
Headache (mild)General disorders168/696—
New generalized muscle pain (mild)General disorders139/679—
Limitation of arm movement (any)Skin and subcutaneous tissue disorders110/679—
Fatigue (moderate)General disorders104/683—

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC
Mean75.3 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female584
Male465
08

Study locations

59 sites
  • Chandler, Arizona 85224, United States
  • Glendale, Arizona 85308, United States
  • Phoenix, Arizona 85028, United States
  • Phoenix, Arizona 85104, United States
  • Rolling Hills Estates, California 90274, United States
  • Apopka, Florida 32703, United States
  • Boynton Beach, Florida 33472, United States
  • Chiefland, Florida 32626, United States
  • Gainesville, Florida 32607, United States
  • Largo, Florida 33770, United States
  • Melbourne, Florida 32935, United States
  • West Palm Beach, Florida 33409, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30342, United States
  • Arkansas City, Kansas 67005, United States
  • Newton, Kansas 67114, United States
  • Wichita, Kansas 67205, United States
  • Wichita, Kansas 67207, United States
  • Crescent Springs, Kentucky 41017, United States
  • New Orleans, Louisiana 70112, United States
  • Nitchitoches, Louisiana 71547, United States
  • Camillus, New York 13031, United States
  • Rochester, New York 14609, United States
  • Raleigh, North Carolina 27609, United States
  • Akron, Ohio 44304, United States
  • Canal Fulton, Ohio 44614, United States
  • Columbus, Ohio 43235, United States
  • Franklin, Ohio 45005, United States
  • Portland, Oregon 97205, United States
  • Pittsburgh, Pennsylvania 15216, United States
  • Goose Creek, South Carolina 29445, United States
  • Mt Pleasant, South Carolina 29464, United States
  • Houston, Texas 77074, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84109, United States
  • Salt Lake City, Utah 84121, United States
  • West Jordan, Utah 84088, United States
  • Bellingham, Virginia 98226, United States
  • Walla Walla, Washington 99362, United States
  • Wenatchee, Washington 98801, United States
  • Berlin-Charlottenburg, 14059, Germany
  • Berlin-Wilmersdorf, 10717, Germany
  • Berlin, 10717, Germany
  • Berlin, 10969, Germany
  • Deggingen, 73326, Germany
  • Frankfurt-am-Main, 60322, Germany
  • Hannover, 30625, Germany
  • Kassel, 34121, Germany
  • Leipzig, 04357, Germany
  • Offenbach, 63071, Germany
  • Wangen, 88239, Germany
  • Wuerzburg, 97070, Germany
  • Arlov, 23234, Sweden
  • Gothenburg, 41136, Sweden
  • Skene, 51162, Sweden
  • Skivarp, 27402, Sweden
  • Stockholm, 11136, Sweden
  • Umea, 90736, Sweden
  • Uppsala, 75185, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years 5 months after primary completion. A results delay was requested in Mar 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2007
First posted
Jul 11, 2007
Start
May 2008
Primary completionActual
Apr 2009
CompletionActual
May 2009
Results delay requested
Mar 2, 2010
Results first posted
Sep 16, 2011
Last update
Sep 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00500266
Lead sponsor
Pfizer
First posted
Jul 11, 2007
Start date
May 2008
Primary completion
Apr 2009
Completion
May 2009
Results posted
Sep 16, 2011
Last update
Sep 16, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion